REG - Hemogenyx Pharma Plc - Result of Audit Tender

Hemogenyx PharmaceuticalsAnnouncement

29/08/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250829:nRSc1349Xa&default-theme=true

RNS Number : 1349X  Hemogenyx Pharmaceuticals PLC  29 August 2025

29 August 2025

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

 

Result of Audit Tender

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce that
following the conclusion of the formal tender process for the role of
statutory auditor, it intends to re-appoint PKF Littlejohn LLP as external
auditor for the financial year ending December 2025 onwards. This will
coincide with the timing of the mandatory lead audit partner rotation.

The audit tender was conducted as a result of the requirement for public
interest entities to undertake an audit tender at least every ten years. A
thorough tender process, overseen by the Audit Committee, was undertaken and
this proposed change of auditor follows a recommendation by the Audit
Committee to the Board based on the outcome of the tender process.

Further details of the audit tender process and evaluation criteria will be
included in the Group's 2025 Annual Report & Accounts. The appointment
will be subject to shareholder approval at the Company's 2026 Annual General
Meeting.

Enquiries:

 

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

 

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City.

The Company is a clinical-stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RTESELFUAEISESA